Streetbeat News

Assets

SPY

USA Durable Goods Orders for July have decreased by 5.2%, which is more than the estimated decrease of 4.0%. The prior figure was a 4.7% increase.

Portfolio Pulse from Happy Mohamed

August 24, 2023 | 12:30 pm

DOGEUSD

SHIBUSD

Former professional football player Antonio Brown declared Shiba Inu (CRYPTO: SHIB) as the next Dogecoin (CRYPTO: DOGE) on May 13, 2021, when SHIB was trading at $0.000019 per coin. Currently, SHIB is trading at $0.000008325. If an investor puts $100 in SHIB today and it reaches the levels when Brown first made his statement, the profit would be $128.23 (128.23%), making the total exit value amount to $228.23.

Portfolio Pulse from Mehab Qureshi

August 24, 2023 | 12:14 pm

BA

SPR

Boeing Co (BA) faces another setback with its 737 MAX due to a supplier-related issue with Spirit Aerosystems Holdings, Inc (SPR). Inappropriately drilled holes have been discovered on the aft pressure bulkhead of the aircraft, causing a delay in deliveries. This issue may also affect Boeing's 2023 goal of rolling out at least 400 737s. Despite the challenges, Boeing continues to dispatch unaffected 737s and Spirit has revamped its production techniques to rectify the issue.

Portfolio Pulse from Anusuya Lahiri

August 24, 2023 | 12:12 pm

PRAA

PRA Group has announced that Rakesh Sehgal will be the company's next CFO, replacing Pete Graham who is leaving the company on September 15, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 12:09 pm

BTCUSD

Bitcoin's recent drop below its 200-day moving average indicates a potential short-term downside, with the $20,000 range once again on the horizon. Katie Stockton of Fairlead Strategies suggests the next key support level for Bitcoin lies around $25,200. If Bitcoin breaks below this level, it could potentially plunge down to $20,600, suggesting a 21% downside from current levels. Bitcoin's fall coincides with a swift decline from just under $30,000 to about $26,000 following news of SpaceX unloading its Bitcoin holdings.

Portfolio Pulse from Benzinga Neuro

August 24, 2023 | 12:02 pm

BZAMF

BZAM Ltd. reported Q2 2023 net revenue of CA$19.3 million ($14.3 million), a 66% YoY increase. However, gross profit decreased by 75% to CA$1.8 million, and the company reported a comprehensive loss of CA$65.6 million. The company is focusing on cost reduction and revenue expansion, and has divested or plans to divest several facilities to reduce expenses.

Portfolio Pulse from Vuk Zdinjak

August 24, 2023 | 11:44 am

C

Citigroup Inc. has made a strategic investment in Rextie, a Peruvian fintech company. The terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 11:02 am

LTH

Life Time Group Holdings (LTH) has had its issuer credit rating upgraded to 'B2' from 'B3' by Moody's Investor Service, citing improving performance and balance sheet improvements. The company also closed a sale-leaseback transaction for $45 million, completing all of the $123 million of previously announced sale-leaseback transactions through August 24, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 10:49 am

ITRG

Integra Resources has completed a stockpile drill program at the DeLamar Project, totaling 12,588 meters in 321 drill holes. The program was designed to test a large portion of the estimated 60 million tonnes of gold and silver mineralized material. The company believes this could increase the heap leach mine life of the project and bolster its economics. An updated mineral resource estimate for DeLamar is expected in Q3 2023, and the Mine Plan of Operations is expected to be submitted in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 10:37 am

RPRX

Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring's Adstiladrin for up to $500 million, comprised of an upfront payment of $300 million and a $200 million milestone payment. The milestone payment is contingent on certain manufacturing goals expected to be achieved in 2025. Royalty Pharma is acquiring a 5.1% royalty on net sales of Adstiladrin in the US, which will increase to 8.0% upon payment of the manufacturing-related milestone.

Portfolio Pulse from Benzinga Newsdesk

August 24, 2023 | 10:33 am